We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Helicobacter Pylori and Iron Deficiency: Prevalence of Association and Effect of Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00475527
Recruitment Status : Withdrawn (problem of accrual)
First Posted : May 21, 2007
Last Update Posted : August 20, 2015
Information provided by:
Hadassah Medical Organization

May 15, 2007
May 21, 2007
August 20, 2015
Not Provided
Not Provided
To compare the raise in hemoglobin level between baseline and eight weeks later in Fe-supplemented and HP-positive children treated for HP infection and Fe-supplemented HP-positive children not treated for HP. [ Time Frame: two years ]
Same as current
Complete list of historical versions of study NCT00475527 on ClinicalTrials.gov Archive Site
1. To determine the prevalence of HP infection in children with IDA in Israel, 2. To compare the demographic, clinical and laboratory findings between children diagnosed with IDA with/without HP infection. [ Time Frame: 2 years ]
Same as current
Not Provided
Not Provided
Helicobacter Pylori and Iron Deficiency: Prevalence of Association and Effect of Therapy
Not Provided

Iron deficiency anemia (IDA) is a major health problem in children, effecting up to 20% of young children. Helicobacter pylori (HP) infection is also reported to be prevalent in children. Several large epidemiologic studies support an association between HP infection and lower iron stores. Other small studies suggest improvement in anemia following HP treatment.

We assume that the prevalence of HP infection in Israeli children diagnosed with IDA is high and that that adding therapy for HP in those children will improve the response to iron deficiency.

This is a prospective randomized control study which will be conducted at six large ambulatory pediatrics clinics from the Jerusalem district. All of the children diagnosed with IDA would be eligible to join the study after informed consent will be obtained. Ethics committee approval is obtained. Analysis of stool samples will be carried out by the HP Stool antigen EIA (HpSA, Premier Platinum HpSA, Meridian Diagnostics inc, Cincinnati, OH, USA). All children enrolled will be treated with standard Fe therapy. Children with positive HpSA will be randomized, controlled for age and clinic, to receive or not receive antibiotics treatment. Assessment of response to iron therapy will be done at eight weeks later. The prevalence of HP infection in children with diagnosed with IDA would be reported. Statistical analysis will compare the baseline data between HP-positive and -negative children and the response to Fe between the three study groups.
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Anemia, Iron-Deficiency
  • Helicobacter Pylori
Drug: omeprazole,clarithromycin,amoxicillin (or metronidazole)
  • No Intervention: iron only
    Only iron therapy
  • Experimental: iron + HP therapy
    Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
    Intervention: Drug: omeprazole,clarithromycin,amoxicillin (or metronidazole)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • All of the children diagnosed with IDA at six large ambulatory pediatrics clinics from the Jerusalem district.
  • The diagnosis of IDA would be defined as a low hemoglobin level in the presence of iron deficiency (low iron levels, high transferrin saturation and/or low ferritin).

Exclusion Criteria:

  • Children with clinical symptoms fo Helicobacter Pylori, i.e. abdominal pain, peptic ulcer etc.
  • Children with underlying chronic disease needing medical treatment.
Sexes Eligible for Study: All
6 Months to 18 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Hadassah Medical Organization
Not Provided
Principal Investigator: Shoshana Revel-Vilk, MD Hadassah Medical Center
Hadassah Medical Organization
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP